Table 1.

Characteristics of AML patients included in this study.

AT AML DIAGNOSIS PRIOR TO TREATMENT (n = 16)
Median age (years)	64 (Range, 36–75)
Cytogenetic risk category at diagnosis
Unfavorable	9 (56%)
Intermediate	7 (44%)
Favorable	0
% Blasts in bone marrow at AML diagnosis	64 (Range, 38–93)
NEWLY DIAGNOSED AML PATIENT WHO RECEIVED INDUCTION CHEMOTHERAPY (n = 9)
Median age (years)	57 (Range, 36–70)
Cytogenetic risk category at diagnosis
Unfavorable	7 (64%)
Intermediate	4 (36%)
Favorable	0
% Blasts in bone marrow at AML diagnosis	72 (Range, 52–93)
AML PATIENTS IN CR DURING CONSOLIDATION THERAPY (n = 10)
Median age (years)	51 (Range, 28–65)
Cytogenetic risk category at diagnosis
Unfavorable	2 (20%)
Intermediate	8 (80%)
Favorable	0
% Blasts in bone marrow at AML diagnosis	53 (Range, 21–83)
AML PATIENT IN CR IN LONG REMISSION AFTER CONSOLIDATION THERAPY (n = 5)
Median age (years)	46 (Range, 33–59)
Cytogenetic risk category at diagnosis
Unfavorable	0
Intermediate	4 (80%)
Favorable	1 (20%)
% Blasts in bone marrow at AML diagnosis	67 (Range, 50–82)